Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia

- Degryse, S., De Bock, C. E., Verrills, N. M., Van Vlierberghe, P., Cools, J., Dun, M. D., Demeyer, S., Govaerts, I., Bornschein, S., Verbeke, D., Jacobs, K., Binos, S., Skerrett-Byrne, D. A., Murray, H. C.

THz astrophysics from Dome A

- Tothill, N. F. H., Kulesa, C. A., Zhu, Z., Bardin, J., Cui, X., Everett, J., Feng, L., Golish, D., Gong, X., Hu, J., Jacobs, K., Jiang, Z., Walker, C. K., Jones, G., Li, Y., Martin, C. L., McCaughrean, M. J., Qin, W., Schein, M., Shang, Z., Siegel, P., Sun, B., Walsh, W., Yang, J., Wang, L., Weinreb, S., Xu, Z., Yan, J., Yuan, X., Zhang, X. -G., Ashley, M. C. B., Lawrence, J. S., Luong-Van, D., Storey, J. W. V., Yang, H., Zhou, X.